

Supplementary material

Snarska W, Jurkowska Z, Bobrowska-Snarska D, et al. Risk factors for SARS-CoV-2 infection in patients with rheumatic diseases. *Pol Arch Intern Med.* 2021; 131: 16147. doi:10.20452/pamw.16147

Supplementary material Table S1. Comparison of parameters of age, disease duration and disease activity in patients with different symptoms of COVID-19

Symptoms of COVID-19	Age, years, median (Q1, Q3)	<i>P</i> value	Disease duration, years, median (Q1, Q3)	<i>P</i> value	VAS pain, mm, median (Q1, Q3)	<i>P</i> value	BASDAI, median (Q1, Q3)	<i>P</i> value	DAS28, mean (SD)	<i>P</i> value	SLEDAI, mean (SD)	<i>P</i> value	
Fever	+	66.5 (59.5, 72.0)	<0.001	2,5 (1.0, 12.5)	0.20	30.0 (15.0, 60.0)	0.47	3.0 (1.0, 5.5)	0.71	3.5 (0.8)	0.25	0	0.10
	-	47.0 (37.0, 60.0)		8.0 (3.0, 12.0)		30.0 (20.0,40.0)		3.0 (1.0, 4.0)		2.8 (1.1)		6.1 (4.2)	
Dyspnea	+	67.0 (60.5, 73.0)	<0.001	5.0 (1.25, 11.0)	0.43	30.0 (30.0, 50.0)	0.50	3.0 (1.0, 5.0)	0.10	3.3 (0.9)	0.53	9.0 (0.0)	0.50

	-	50.0 (37.0, 60.0)		8 (2.0, 13.0)		30.0 (20.0, 40.0)		3.0 (1.0, 4.0)		2.9 (1.1)		5.8 (4.3)	
Cough	+	63.0 (45.0, 70.5)	0.009	7.5 (2.0, 12.0)	0.77	30.0 (30.0, 40.0)	0.75	2.0 (1.0, 4.0)	0.46	2.9 (0.9)	0.91	6.5 (3.5)	0.89
	-	50.0 (36.0, 60.0)		6.0 (2.0, 12.0)		0 (15.0, 45.0)		4 (1.0, 6.0)		2.9 (1.2)		6.0 (4.6)	
Weakness	+	59.0 (47.0, 67.0)	0.003	5.0 (2.0, 10.0)	0.04	30.0 (30.0, 40.0)	0.009	4.5 (1.2, 5.5)	0.14	3.1 (1.1)	0.22	8.0 (4.4)	0.14
	-	41.0 (35.0, 50.0)		10.5 (3.0, 15.0)		10.0 (10.0, 30.0)		1.0 (1.0, 3.0)		2.5 (1.1)		3.8 (2.9)	
Smell loss	+	48.0 (37.0, 61.0)	0.02	7 (3.0, 12.0)	0.18	30.0 (10.0, 40.0)	0.008	1 (1.0, 4.0)	0.23	2.8 (0.9)	0.25	7.8 (3.9)	0.08
	-	61.0 (50.0, 66.0)		3.5 (1.0, 9.0)		40 (30.0, 70.0)		4.5 (3.0, 6.0)		3.4 (1.4)		2.7 (2.3)	
Taste loss	+	49.50 (36.0,	0.06	6.5 (2.0, 9.0)	0.75	30.0 (10.0, 40.0)	0.008	1.0 (1.0, 4.0)	0.23	2.8 (0.9)	0.41	7.8 (4.9)	0.33

		61.0)											
	-	60 (50.0, 64.0)		8 (2.0, 12.0)		40.0 (30.0, 70.0)		4.5 (3.0, 6.0)		3.2 (1.4)		4.8 (3.4)	
Muscle pain	+	55 (45.0, 63.0)	0.60	7 (2.0, 10.0)	0.98	30.0 (30.0, 40.0)	0.90	3.0 (1.0, 5.0)	0.10	3.7 (1.1)	0.01	8 (5.1)	0.25
	-	51.5 (39.0, 64.0)		6.5 (2.0, 13.0)		30.0 (20.0, 40.0)		3.0 (1.0, 4.0)		2.5 (0.9)		4.6 (3.1)	
Headache	+	53 (39.0, 61.0)	0.45	9 (2.0, 13.0)	0.51	30.0 (20.0, 40.0)	0.95	1.0 (1.0, 1.0)	0.10	3.1 (1.3)	0.56	8 (4.4)	0.14
	-	56.5 (41.0, 67.0)		6 (2.0, 11.0)		30.0 (20.0, 40.0)		3.5 (1.0, 5.0)		2.8 (0.9)		3.8 (2.9)	
Joint pain	+	60 (45.0, 63.0)	0.39	6 (2.0, 9.0)	0.30	30.0 (30.0, 50.0)	0.52	0.0	0.10	3.1 (1.2)	0.01	7 (8.5)	0.76
	-	50.5 (39.0, 66.0)		7.5 (3.0, 13.0)		30.0 (10.0, 40.0)		3.0 (1.0, 5.0)		2.8 (1.1)		5.86 (3.3)	

Abbreviations: BASDAI, Bath ankylosing spondilitis disease activity index; SLEDAI, systemic lupus erythematosus disease activity index; VAS, visual analogue scale

Supplementary material Table S2. The results of univariable analysis of risk factors on odds of COVID-19 in patients with rheumatic diseases

Covariates	OR (95% CI)	<i>P</i> value
Disease duration 3-15 years vs < 3 years	0.56 (0.27 – 1.19)	0.1
Disease duration > 15 years vs < 3 years	0.24 (0.08 – 0.69)	0.008
SpA	0.43 (0.21 – 0.84)	0.01
RA	1.35 (0.71 – 2.59)	0.36
CTD	1.67 (0.85 – 3.28)	0.13
Comorbidities	1.2 (0.64 – 2.26)	0.57
Hypothyroidism	2.35 (1.09 – 5.06)	0.03
CHD	0.73 (0.23 – 2.29)	0.58
SSZ	0.37 (0.15 – 0.88)	0.02
NSAIDs	0.34 (0.14 – 0.79)	0.01
MTX	0.99 (0.53 – 1.83)	0.97
CQ	2.91 (1.16 – 7.30)	0.02
CS ≤ 10 mg/day vs 0 mg/day	0.29 (0.08 – 1.04)	0.03
CS > 10 mg/day vs 0 mg/day	1.82 (0.94 – 3.55)	0.04

TCZ	1.22 (0.30 – 4.89)	0.77
Cigarettes smoking	0.68 (0.24 – 1.09)	0.45
Hypertension	1.07 (0.56 – 2.04)	0.84
VAS pain \geq 40 mm vs VAS pain $<$ 40 mm	0.95 (0.46 – 1.94)	0.88
DAS28 2.6 – 3.3 vs DAS28 $<$ 2.6	0.86 (0.26 – 2.85)	0.80
DAS28 3.21 – 5.1 vs DAS28 $<$ 2.6	0.86 (0.26 – 2.85)	0.80
DAS28 $>$ 5.1 vs DAS28 $<$ 2.6	0.26 (0.02 – 2.3)	0.22
BASDAI \geq 4 vs BASDAI $<$ 4	1.27 (0.25 – 6.39)	0.77
BMI 25 – 29.99 vs BMI \leq 24.99	1.29 (0.68 – 2.44)	0.45
BMI 30 – 34.99 vs BMI \leq 24.99	0.67 (0.24 – 1.89)	0.45
BMI 35 – 39.99 vs BMI \leq 24.99	0.38 (0.01 – 1.5)	0.10

Abbreviations: BASDAI, Bath ankylosing spondylitis disease activity index; BMI, body mass index; CHD, coronary heart disease; CQ, chloroquine; CS, corticosteroids; CTD, connective tissue diseases; DAS28, disease activity score 28; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SpA, spondyloarthritis; SSZ, sulfasalazine; VAS, visual analogue scale; vs, versus.